Clinical Trial

Single-dose,First-in-human of KLA478

Name: Single-dose,First-in-human of KLA478 — clinical trial record (NCT07240675)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the safety and tolerability and pharmacokinetics of single doses of KLA478 in healthy volunteers；

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2025-11-18; most recent amendment 2026-05-21.

Status change: Not Yet Recruiting → Recruiting 2026-02-24

Trial Details

NCT Number	NCT07240675
Lead Sponsor	Hunan Kelun Pharmaceutical Co., Ltd.
Conditions	Healthy Volunteers
Enrollment	40 participants
Start Date	2025-11-26
Primary Completion	2026-09-30 (estimated)
Study Completion	2026-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-26